24.71
Schlusskurs vom Vortag:
$25.19
Offen:
$25.28
24-Stunden-Volumen:
6.68M
Relative Volume:
0.61
Marktkapitalisierung:
$10.36B
Einnahmen:
$5.06B
Nettoeinkommen (Verlust:
$-2.22B
KGV:
-4.2466
EPS:
-5.82
Netto-Cashflow:
$-3.96B
1W Leistung:
+0.88%
1M Leistung:
-28.80%
6M Leistung:
-54.92%
1J Leistung:
-76.11%
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MRNA
Moderna Inc
|
24.71 | 10.36B | 5.06B | -2.22B | -3.96B | -5.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-13 | Eingeleitet | Citigroup | Neutral |
2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
2024-12-18 | Herabstufung | Argus | Buy → Hold |
2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
2024-11-19 | Eingeleitet | Berenberg | Hold |
2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
2023-06-26 | Hochstufung | UBS | Neutral → Buy |
2023-04-26 | Eingeleitet | Guggenheim | Neutral |
2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
2022-01-21 | Eingeleitet | UBS | Neutral |
2021-12-07 | Eingeleitet | Cowen | Market Perform |
2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-07-15 | Bestätigt | Jefferies | Hold |
2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-12-09 | Herabstufung | Needham | Buy → Hold |
2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-07-13 | Eingeleitet | Jefferies | Buy |
2020-06-30 | Eingeleitet | Argus | Buy |
2020-06-08 | Eingeleitet | Barclays | Overweight |
2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
2019-10-25 | Eingeleitet | ROTH Capital | Buy |
2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna sues construction firm claiming leaks, mold at new drug plant - NBC Boston
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Bank of Montreal Can - MarketBeat
Bridgewater Associates LP Invests $25.19 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Water leaks, mold plague Moderna's new manufacturing site, lawsuit claims - The Business Journals
Scotia Capital Inc. Decreases Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Russell Investments Group Ltd. Has $7.02 Million Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years - Benzinga
Invesco Ltd. Acquires 979,858 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Says New Drug Plant Riddled With Defects, Mold - Law360
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Legal & General Group Plc - MarketBeat
Moderna (MRNA) Leads Healthcare Short Interest in March - GuruFocus
Lansdowne Partners UK LLP Acquires New Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Advisory Services Network LLC - MarketBeat
Quinn Opportunity Partners LLC Invests $686,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Neuberger Berman Group LLC Reduces Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Bloom Energy, Rogers, 3D Systems, Moderna, and EchoStar Stocks Trade Down, What You Need To Know - The Globe and Mail
Moderna permitted to start commercial mRNA vaccine manufacture in UK - The Pharma Letter
Leerink Partners Adjusts Moderna Price Target to $23 From $27, Maintains Underperform Rating - MarketScreener
Moderna Co-Founder and MIT Legend Strengthens Decoy Therapeutics Drug Development Team - Stock Titan
MRNA Based Vaccines and Therapeutics Therapeutics Market Size - openPR.com
Renaissance Technologies LLC Purchases 700,458 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
APG Asset Management N.V. Buys 203,792 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
FDA Special Assistant Høeg’s Vaccine Concerns On Display At ACIP - insights.citeline.com
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Shelton Capital Management - MarketBeat
Goldman Sachs Adjusts Moderna's Price Target to $35 From $49, Keeps Neutral Rating - MarketScreener
Redburn Atlantic Adjusts Moderna's Price Target to $52 From $55, Keeps Neutral Rating - MarketScreener
Morgan Stanley Issues Pessimistic Forecast for Moderna (NASDAQ:MRNA) Stock Price - MarketBeat
Aviva PLC Lowers Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Resona Asset Management Co. Ltd. Buys Shares of 94,753 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Fmr LLC Has $776.08 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Sit Investment Associates Inc. Sells 10,675 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Sets New 1-Year LowTime to Sell? - MarketBeat
Lobbying Update: $50,000 of MODERNA US INC. lobbying was just disclosed - Nasdaq
Aster Capital Management DIFC Ltd Takes Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
RFK Jr Asks If Taxpayer-Funded Healthcare Should Be Accessible To People Smoking 'Three Packs A Day' - Benzinga
First Week of May 30th Options Trading For Moderna (MRNA) - Nasdaq
ExodusPoint Capital Management LP Purchases New Shares in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
National Bank of Canada FI Decreases Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Himension Capital Singapore PTE. LTD. Purchases 21,102 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Titleist Asset Management LLC Has $1.31 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna to Report First Quarter 2025 Financial Results on Thursd - GuruFocus
Schroder Investment Management Group Sells 103,486 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
Novavax (NVAX) Shares Plunge After RFK Jr. Questions Its Covid Vaccine Efficacy - Bloomberg.com
MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is Moderna Stock A Sell After The FDA's 'Bloodbath?' - Investor's Business Daily
Japan approves Moderna COVID vaccine as booster, Novavax files for 1st approval - tuoitrenews.vn
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - Eagle-Tribune
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moderna Inc-Aktie (MRNA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
SAGAN PAUL | Director |
Mar 03 '25 |
Buy |
31.76 |
31,620 |
1,004,251 |
312,027 |
Klinger Shannon Thyme | Chief Legal Officer |
Dec 09 '24 |
Sale |
44.68 |
529 |
23,637 |
20,446 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):